Location History:
- Halle/Saale, DE (2003 - 2008)
- Halle, DE (2007 - 2021)
Company Filing History:
4 out of 71 
1 out of 16 
1 out of 1 Years Active: 2003-2025
Title: Dagmar Schlenzig: Innovator in Pharmaceutical Research
Introduction
Dagmar Schlenzig is a prominent inventor based in Halle/Saale, Germany. She has made significant contributions to the field of pharmaceutical research, particularly in the development of novel compounds for medical applications. With a total of six patents to her name, Schlenzig's work focuses on innovative solutions for various health conditions.
Latest Patents
Among her latest patents, Schlenzig has developed inhibitors of meprin α and β. This invention relates to novel hydroxamic acid derivatives that serve as inhibitors of meprin β and/or α. The pharmaceutical compositions comprising these compounds are aimed at treating or preventing diseases associated with meprin β and/or α. Another notable patent involves effectors of dipeptidyl peptidase IV for topical use. This invention includes compounds designed to influence the activity of dipeptidyl peptidase, targeting local immunological processes such as chemotaxis and inflammatory diseases. These compounds are intended for effective treatment of conditions like psoriasis, periodontitis, arthritis, and allergies.
Career Highlights
Throughout her career, Dagmar Schlenzig has worked with notable companies in the pharmaceutical industry, including Probiodrug AG and Prosidion Limited. Her expertise and innovative approach have positioned her as a key figure in her field.
Collaborations
Schlenzig has collaborated with esteemed colleagues such as Hans-Ulrich Demuth and Torsten Hoffmann. These partnerships have further enhanced her research and development efforts.
Conclusion
Dagmar Schlenzig's contributions to pharmaceutical research exemplify her dedication to innovation and improving health outcomes. Her patents reflect a commitment to addressing complex medical challenges through scientific advancement.